Xinpei Liu1, Yiming Shen2, Xuqian Zhang3, Rui Lin1, Qiang Jia2, Yixiang Chang1, Wenge Liu4, Wentian Liu5. 1. Department of Gastroenterology, Tianjin Medical University General Hospital, Tianjin, 300052, China. 2. Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, 300052, China. 3. Department of Gastroenterology and Hepatology, No. 731 Hospital of CASIC, Beijing, 100074, China. 4. Department of Biomedical Engineering, Duke University, Durham, NC, 27708, USA. 5. Department of Gastroenterology, Tianjin Medical University General Hospital, Tianjin, 300052, China. lwentian64@163.com.
Abstract
BACKGROUND: Brachytherapy is a targeted type of radiotherapy utilized in the treatment of cancers. Elastin-like polypeptides are a unique class of genetically engineered peptide polymers that have several attractive properties for brachytherapy. AIMS: To explore the feasibility and application of brachytherapy for VX2 liver tumor using elastin-like polypeptides with (131)I so as to provide reliable experimental evidence for a new promising treatment of liver cancer. METHODS: Elastin-like polypeptide as carrier was labeled with (131)I using the iodogen method. Ten eligible rabbits with VX2 liver tumor were randomly divided into the treatment group (n = 5) and control group (n = 5). The treatment group received brachytherapy using elastin-like polypeptide with (131)I, and in the control group, elastin-like polypeptide was injected into the VX2 liver tumor as a control. Periodic biochemical and imaging surveillances were required to assess treatment efficacy. RESULTS: The stability of elastin-like polypeptide with (131)I in vitro was maintained at over 96.8 % for 96 h. Biochemistry and imaging indicated brachytherapy using elastin-like polypeptide with (131)I for liver tumor can improve liver function and inhibit tumor growth (P < 0.05). CONCLUSIONS: Elastin-like polypeptide can be an ideal carrier of (131)I and have high labeling efficiency, radiochemical purity and stability. Brachytherapy using elastin-like polypeptide with (131)I for liver tumor is a useful therapy that possesses high antitumor efficacy advantages.
BACKGROUND: Brachytherapy is a targeted type of radiotherapy utilized in the treatment of cancers. Elastin-like polypeptides are a unique class of genetically engineered peptide polymers that have several attractive properties for brachytherapy. AIMS: To explore the feasibility and application of brachytherapy for VX2 liver tumor using elastin-like polypeptides with (131)I so as to provide reliable experimental evidence for a new promising treatment of liver cancer. METHODS:Elastin-like polypeptide as carrier was labeled with (131)I using the iodogen method. Ten eligible rabbits with VX2 liver tumor were randomly divided into the treatment group (n = 5) and control group (n = 5). The treatment group received brachytherapy using elastin-like polypeptide with (131)I, and in the control group, elastin-like polypeptide was injected into the VX2 liver tumor as a control. Periodic biochemical and imaging surveillances were required to assess treatment efficacy. RESULTS: The stability of elastin-like polypeptide with (131)I in vitro was maintained at over 96.8 % for 96 h. Biochemistry and imaging indicated brachytherapy using elastin-like polypeptide with (131)I for liver tumor can improve liver function and inhibit tumor growth (P < 0.05). CONCLUSIONS:Elastin-like polypeptide can be an ideal carrier of (131)I and have high labeling efficiency, radiochemical purity and stability. Brachytherapy using elastin-like polypeptide with (131)I for liver tumor is a useful therapy that possesses high antitumor efficacy advantages.
Authors: Peter Ferenci; Michael Fried; Douglas Labrecque; J Bruix; M Sherman; M Omata; J Heathcote; T Piratsivuth; Mike Kew; Jesse A Otegbayo; S S Zheng; S Sarin; S Hamid; Salma Barakat Modawi; Wolfgang Fleig; Suliman Fedail; Alan Thomson; Aamir Khan; Peter Malfertheiner; George Lau; F J Carillo; Justus Krabshuis; Anton Le Mair Journal: J Gastrointestin Liver Dis Date: 2010-09 Impact factor: 2.008
Authors: Piyush Koria; Hiroshi Yagi; Yuko Kitagawa; Zaki Megeed; Yaakov Nahmias; Robert Sheridan; Martin L Yarmush Journal: Proc Natl Acad Sci U S A Date: 2010-12-30 Impact factor: 11.205
Authors: Wenge Liu; Jonathan McDaniel; Xinghai Li; Daisuke Asai; Felipe Garcia Quiroz; Jeffery Schaal; Ji Sun Park; Michael Zalutsky; Ashutosh Chilkoti Journal: Cancer Res Date: 2012-11-15 Impact factor: 12.701
Authors: Sarah Keller; Tabea Borde; Julia Brangsch; Carolin Reimann; Avan Kader; Daniel Schulze; Rebecca Buchholz; Jan O Kaufmann; Uwe Karst; Eyk Schellenberger; Bernd Hamm; Marcus R Makowski Journal: Sci Rep Date: 2020-11-27 Impact factor: 4.379